Lista de obras - Barbro K Linderholm - Dominio Público Uruguay

A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns

scientific article published on 10 June 2020

A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

artículo científico publicado en 2011

Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen

artículo científico publicado en 2006

Alterations of the immunoglobulin heavy chain locus in progressive B-cell lymphomas.

artículo científico publicado en 1998

An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.

artículo científico publicado en 2008

Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel.

artículo científico publicado en 2013

Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer

scientific article published on 07 January 2014

Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer

Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis.

artículo científico publicado en 2013

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy

artículo científico publicado en 2013

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial

artículo científico publicado en 2011

Molecular profiling of male breast cancer - lost in translation?

artículo científico

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment

artículo científico publicado en 2004

Person and Family Centeredness in Ethiopian Cancer Care: Proposal for a Project for Improving Communication, Ethics, Decision Making, and Health

scientific article published on 19 May 2020

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.

artículo científico publicado en 2010

Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

artículo científico publicado en 2013

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.

artículo científico publicado en 2013

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

artículo científico publicado en 2009

Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

artículo científico publicado en 2021

Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers

artículo científico publicado en 2004

Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.

artículo científico publicado en 2008

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer.

artículo científico publicado en 2010

Weekly taxanes--a leap forward or a minute progress?

artículo científico publicado en 2004

Lista de obras de Barbro K Linderholm

A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns

A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen

Alterations of the immunoglobulin heavy chain locus in progressive B-cell lymphomas.

An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.

Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel.

Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer

Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer

Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis.

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial

Molecular profiling of male breast cancer - lost in translation?

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment

Person and Family Centeredness in Ethiopian Cancer Care: Proposal for a Project for Improving Communication, Ethics, Decision Making, and Health

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.

Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers

Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer.

Weekly taxanes--a leap forward or a minute progress?